<p>无论您的投资风格如何，我们都希望能找到被忽视的股票宝石。这些地方是获利最丰厚的地方。但是找到这些股票可能是一项挑战。拥有投资者在 30 年前只能梦想到的信息是一把双刃剑。很难区分隐藏的宝石和被炒作过度的垃圾股。</p>
<p>在这种时候，跟随分析师的情绪可能会有所帮助。但是，根据定义，被忽视的股票是分析师要么忽视的股票，要么因为错误的原因而对其持负面态度。在本文中，我将关注那些在过去 60 天中被一个或多个分析师降级或调低目标价的股票。</p>
<p>分析师经常短视。在这个群体中，买传闻卖消息是很常见的。然而，如果您玩的是长期游戏，并且有适当的风险承受能力，您可以找到像下面列出的这三只被忽视的股票宝石。</p>
<h2>Pure Storage（PSTG）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>图片来源：Tada Images / Shutterstock</p>
<p><strong>Pure Storage</strong>（纽约证券交易所：<strong>PSTG</strong>）可能看起来是被忽视的股票宝石名单中的一个奇怪选择。PSTG 股价在过去 12 个月上涨了 73%，在 2024 年上涨了 81%。这使得该股更有可能被高估而不是低估。这也是分析师们似乎相信的。</p>
<p>该公司发布了一份扎实的财报，年度收入和利润均同比增长。但是，与 <strong>Palantir Technologies</strong>（纽约证券交易所：<strong>PLTR</strong>）类似，一些分析师认为增长不足以证明进一步的股价增长。在过去 30 天里，<strong>摩根大通</strong>（纽约证券交易所：<strong>MS</strong>）和 <strong>瑞士银行集团</strong>（纽约证券交易所：<strong>UBS</strong>）已经将该股降级，瑞士银行集团甚至给予该股一个罕见的卖出评级。</p>
<p>人们认为 Pure Storage 将很难以足以证明其估值的激进速度增长。增加这一担忧的是该公司所处的数据中心领域的竞争日益激烈。</p>
<p>尽管如此，分析师们普遍看好 PSTG 股票，并对其有比当前价格高 9% 的共识目标价。</p>
<h2>Paramount Global（PARA）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/uploads/2024/05/paramount-300x152.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/uploads/2024/05/paramount-300x152.png"/></p>
<p>当分析师以卖出评级开始覆盖股票时，总是令人担忧。然而，这正是发生在 <strong>Paramount Global</strong>（纳斯达克证券交易所：<strong>PARA</strong>）身上的事。6 月 25 日，<strong>高盛</strong>（纽约证券交易所：<strong>GS</strong>）以卖出评级和 9.50 美元的目标价开始覆盖 PARA 股票。这是在 <strong>富国银行</strong>（纽约证券交易所：<strong>WFC</strong>）将 PARA 股票降级为低配并给予 9 美元的价格标签之后。</p>
<p>围绕 Paramount 的问题对于任何关注该股票的人都是众所周知的。在正在发生的流媒体行业的强强对话中，该公司被留下了。它找不到买家。最公开的指责是随着与其大股东 <strong>Skydance</strong> 合并的谈判破裂。</p>
<p>但情况可能正在发生变化。PARA 股票在合并消息传出后上涨。虽然仍有许多障碍需要克服，但如果 Paramount 在流媒体领域有一个可行的位置，它可能成为 2024 年被忽视的股票宝石之一。</p>
<h2>2seventy bio（TSVT）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>图片来源：Matej Kastelic / Shutterstock</p>
<p>如果您正在寻找被忽视的股票宝石，那么低价股是一个不错的起点。这对于 <strong>2seventy bio</strong>（纳斯达克证券交易所：<strong>TSVT</strong>）来说就是这种情况。这家细胞和基因疗法公司市值仅为 2.06 亿美元，但它有收入——这是许多同等规模公司无法声称的。</p>
<p>在这种情况下，该公司获得了 Abecma 的 FDA 批准。这是一种用于晚期多发性骨髓瘤患者的细胞疗法。该公司与 <strong>百时美施贵宝</strong>（纽约证券交易所：<strong>BMY</strong>）合作开发了这种疗法。更重要的是，2seventy bio 最近获得了 Abecma 的扩展标签，可能会增加收入。</p>
<p>这对至少一位分析师来说还不足以安抚。6 月 6 日，高盛将 TSVT 股票的评级从中性调低为卖出，并设定了 2 美元的新目标价。即使 <strong>Wedbush</strong> 保持中性评级，分析师们也只给出 5 美元的目标价。</p>
<p>对于一家在利率仍然较高的时候没有盈利的公司来说，这并不是独特的。但是朝着盈利的持续进展以及利率下调可能足以使这些降级看起来过度。</p>
<p>_在发布日期，Chris Markoch 持有 PLTR 的多头头寸。本文中表达的观点属于作者个人，遵守 InvestorPlace.com 的发布准则。</p>
<p>_在发布日期，负责编辑在本文提到的证券中没有（直接或间接）任何头寸。</p>
<p>Chris Markoch 是一名自由金融撰稿人，已经覆盖市场超过五年。他自 2019 年以来一直为 InvestorPlace 撰写文章。</p>

PSTG

派拉蒙环球

PARAA

TSVT

<p>华尔街忽视的 3 个潜力股：本文讨论了分析师在过去 60 天内下调评级或降低目标股价的被忽视的潜力股。文章重点介绍了三家公司：Pure Storage（PSTG）、Paramount Global（PARA）和 2seventy bio（TSVT）。文章提供了关于分析师情绪以及下调评级背后的原因的信息，同时还探讨了这些股票的潜在增长机会</p>

<p>No matter your investing style, we all hope to find overlooked stock gems. These are where the biggest gains are made. But finding these stocks can be a challenge. Having access to information investors could only have dreamt of 30 years ago is a double-edged sword. It can be difficult to distinguish between hidden gems and hyped-up junk.</p>
<div class="lb-trans"><p>无论您的投资风格如何，我们都希望能找到被忽视的股票宝石。这些地方是获利最丰厚的地方。但是找到这些股票可能是一项挑战。拥有投资者在 30 年前只能梦想到的信息是一把双刃剑。很难区分隐藏的宝石和被炒作过度的垃圾股。</p>
</div><p>At times like these, it can be useful to follow analyst sentiment. But, by definition, overlooked stocks are stocks that either analysts ignore, or they’ve turned negative on for the wrong reason(s). For this article, I’m looking at stocks that one or more analysts have downgraded or lowered their price target in the last 60 days.</p>
<div class="lb-trans"><p>在这种时候，跟随分析师的情绪可能会有所帮助。但是，根据定义，被忽视的股票是分析师要么忽视的股票，要么因为错误的原因而对其持负面态度。在本文中，我将关注那些在过去 60 天中被一个或多个分析师降级或调低目标价的股票。</p>
</div><p>Analysts frequently think short-term. Buying the rumor and selling the news is common among this group. However, if you play the long game and you have a suitable risk tolerance, you can find overlooked stock gems like the three listed below.</p>
<div class="lb-trans"><p>分析师经常短视。在这个群体中，买传闻卖消息是很常见的。然而，如果您玩的是长期游戏，并且有适当的风险承受能力，您可以找到像下面列出的这三只被忽视的股票宝石。</p>
</div><h2>Pure Storage (PSTG)</h2>
<div class="lb-trans"><h2>Pure Storage（PSTG）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Tada Images / Shutterstock</p>
<div class="lb-trans"><p>图片来源：Tada Images / Shutterstock</p>
</div><p><strong>Pure Storage</strong> (NYSE:<strong>PSTG</strong>) may seem to be an odd choice for a list of overlooked stock gems. The PSTG stock price is up 73% in the last 12 months and 81% in 2024. That would make the stock more likely to be overvalued than undervalued. And that’s what the analysts seem to believe.</p>
<div class="lb-trans"><p><strong>Pure Storage</strong>（纽约证券交易所：<strong>PSTG</strong>）可能看起来是被忽视的股票宝石名单中的一个奇怪选择。PSTG 股价在过去 12 个月上涨了 73%，在 2024 年上涨了 81%。这使得该股更有可能被高估而不是低估。这也是分析师们似乎相信的。</p>
</div><p>The company reported a solid earnings report with year-over-year gains on the top and bottom lines. But, in a similar vein to <strong>Palantir Technologies</strong> (NYSE:<strong>PLTR</strong>), some analysts believe the growth is not enough to justify further stock price growth. In the last 30 days, <strong>Morgan Stanley</strong> (NYSE:<strong>MS</strong>) and <strong>UBS Group</strong> (NYSE:<strong>UBS</strong>) have downgraded the stock, with UBS giving the stock a rare Sell rating.</p>
<div class="lb-trans"><p>该公司发布了一份扎实的财报，年度收入和利润均同比增长。但是，与 <strong>Palantir Technologies</strong>（纽约证券交易所：<strong>PLTR</strong>）类似，一些分析师认为增长不足以证明进一步的股价增长。在过去 30 天里，<strong>摩根大通</strong>（纽约证券交易所：<strong>MS</strong>）和 <strong>瑞士银行集团</strong>（纽约证券交易所：<strong>UBS</strong>）已经将该股降级，瑞士银行集团甚至给予该股一个罕见的卖出评级。</p>
</div><p>The belief is that Pure Storage will have a hard time growing at the aggressive pace needed to justify its valuation. Adding to that concern is the growing competition in the data center space that the company occupies.</p>
<div class="lb-trans"><p>人们认为 Pure Storage 将很难以足以证明其估值的激进速度增长。增加这一担忧的是该公司所处的数据中心领域的竞争日益激烈。</p>
</div><p>Nevertheless, analysts are generally bullish on the PSTG stock and have a consensus price target of 9% higher than its current price.</p>
<div class="lb-trans"><p>尽管如此，分析师们普遍看好 PSTG 股票，并对其有比当前价格高 9% 的共识目标价。</p>
</div><h2>Paramount Global (PARA)</h2>
<div class="lb-trans"><h2>Paramount Global（PARA）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/uploads/2024/05/paramount-300x152.png" alt="" original-src="https://investorplace.com/wp-content/uploads/2024/05/paramount-300x152.png"/></p>
<p>It’s always cause for concern when analysts initiate their coverage with a Sell rating. However, that’s exactly what happened to <strong>Paramount Global</strong>(NASDAQ:<strong>PARA</strong>). On June 25, <strong>Goldman Sachs</strong>(NYSE:<strong>GS</strong>) initiated coverage on PARA stock with a Sell rating and a $9.50 price target. That comes after <strong>Wells Fargo</strong>(NYSE:<strong>WFC</strong>) downgraded PARA stock to Underweight and slapped a $9 price tag on the stock.</p>
<div class="lb-trans"><p>当分析师以卖出评级开始覆盖股票时，总是令人担忧。然而，这正是发生在 <strong>Paramount Global</strong>（纳斯达克证券交易所：<strong>PARA</strong>）身上的事。6 月 25 日，<strong>高盛</strong>（纽约证券交易所：<strong>GS</strong>）以卖出评级和 9.50 美元的目标价开始覆盖 PARA 股票。这是在 <strong>富国银行</strong>（纽约证券交易所：<strong>WFC</strong>）将 PARA 股票降级为低配并给予 9 美元的价格标签之后。</p>
</div><p>The issues surrounding Paramount are well-known to anyone following the stock. In the game of musical chairs that is happening in the streaming industry, the company is left without a chair. It can’t find a buyer. The most public rebuke came as talks of merging with its majority shareholder, <strong>Skydance</strong>, fell through.</p>
<div class="lb-trans"><p>围绕 Paramount 的问题对于任何关注该股票的人都是众所周知的。在正在发生的流媒体行业的强强对话中，该公司被留下了。它找不到买家。最公开的指责是随着与其大股东 <strong>Skydance</strong> 合并的谈判破裂。</p>
</div><p>But that may be changing. PARA stock is moving higher on news that the merger is back on. There are still many obstacles to clear, but if Paramount has a viable place in the streaming landscape, it may become one of the overlooked stock gems of 2024.</p>
<div class="lb-trans"><p>但情况可能正在发生变化。PARA 股票在合并消息传出后上涨。虽然仍有许多障碍需要克服，但如果 Paramount 在流媒体领域有一个可行的位置，它可能成为 2024 年被忽视的股票宝石之一。</p>
</div><h2>2seventy bio (TSVT)</h2>
<div class="lb-trans"><h2>2seventy bio（TSVT）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Matej Kastelic / Shutterstock</p>
<div class="lb-trans"><p>图片来源：Matej Kastelic / Shutterstock</p>
</div><p>If you’re looking for overlooked stock gems, penny stocks are a good place to start. That’s the case for <strong>2seventy bio</strong> (NASDAQ:<strong>TSVT</strong>). The cell and gene therapy company has just a $206 million market cap, but it has revenue — which is something many companies its size cannot claim.</p>
<div class="lb-trans"><p>如果您正在寻找被忽视的股票宝石，那么低价股是一个不错的起点。这对于 <strong>2seventy bio</strong>（纳斯达克证券交易所：<strong>TSVT</strong>）来说就是这种情况。这家细胞和基因疗法公司市值仅为 2.06 亿美元，但它有收入——这是许多同等规模公司无法声称的。</p>
</div><p>In this case, the company received FDA approval for Abecma. It’s a cellular therapy for advanced-stage multiple myeloma patients. The company developed the therapy as part of its collaboration with <strong>Bristol Myers Squibb</strong> (NYSE:<strong>BMY</strong>). Better still, 2seventy bio recently received an expanded label for Abecma that may increase revenue.</p>
<div class="lb-trans"><p>在这种情况下，该公司获得了 Abecma 的 FDA 批准。这是一种用于晚期多发性骨髓瘤患者的细胞疗法。该公司与 <strong>百时美施贵宝</strong>（纽约证券交易所：<strong>BMY</strong>）合作开发了这种疗法。更重要的是，2seventy bio 最近获得了 Abecma 的扩展标签，可能会增加收入。</p>
</div><p>That hasn’t been enough to placate at least one analyst. On June 6, Goldman Sachs downgraded TSVT stock from a Neutral to a Sell with a new price target of $2. And even with <strong>Wedbush</strong> maintaining its Neutral rating, analysts only give the stock a $5 price target.</p>
<div class="lb-trans"><p>这对至少一位分析师来说还不足以安抚。6 月 6 日，高盛将 TSVT 股票的评级从中性调低为卖出，并设定了 2 美元的新目标价。即使 <strong>Wedbush</strong> 保持中性评级，分析师们也只给出 5 美元的目标价。</p>
</div><p>This isn’t unique for a company that is unprofitable at a time when interest rates remain high. But continued progress towards profitability combined with a rate cut may be enough to make these downgrades look overdone.</p>
<div class="lb-trans"><p>对于一家在利率仍然较高的时候没有盈利的公司来说，这并不是独特的。但是朝着盈利的持续进展以及利率下调可能足以使这些降级看起来过度。</p>
</div><p><em>On the date of publication, Chris Markoch had a long position in PLTR. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.</em></p>
<div class="lb-trans"><p>_在发布日期，Chris Markoch 持有 PLTR 的多头头寸。本文中表达的观点属于作者个人，遵守 InvestorPlace.com 的发布准则。</p>
</div><p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div class="lb-trans"><p>_在发布日期，负责编辑在本文提到的证券中没有（直接或间接）任何头寸。</p>
</div><p>Chris Markoch is a freelance financial copywriter who has been covering the market for over five years. He has been writing for InvestorPlace since 2019.</p>
<div class="lb-trans"><p>Chris Markoch 是一名自由金融撰稿人，已经覆盖市场超过五年。他自 2019 年以来一直为 InvestorPlace 撰写文章。</p>
</div>

华尔街忽视的三只隐藏股票瑰宝